Why the study?
Does tirofiban improve safety and late survival in patients with acute moderate ischemic stroke?
Does tirofiban improve safety and late survival in patients with acute moderate ischemic stroke?
Tirofiban appears safe and may improve late survival in patients with acute moderate ischemic stroke, even with delayed administration.
May support delayed tirofiban safety in moderate stroke but should not change practice; leaves open randomized confirmation of late survival.
We conclude that tirofiban might be safe in acute moderate ischemic stroke even when administered within a large time window after symptom onset and might save lives in the late outcome. Clinical Trial Registration- URL: www.strokecenter.org/trials/. Trial name: SaTIS. Enrollment began before July 1, 2005.
No takes yet. Share an insight, caveat, or question.
Siebler et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: